Cognitive Decline Not Slowed by Ginkgo Biloba

Article

Newly published study results show that use of the herbal supplement for several years in patients age 72-96 did not result in a slower rate of cognitive decline than placebo.

"Ginkgo biloba is marketed widely and used with the hope of improving, preventing, or delaying cognitive impairment associated with aging and neurodegenerative disorders such as Alzheimer disease. Indeed, in the United States and particularly in Europe, G biloba is perhaps the most widely used herbal treatment consumed specifically to prevent age-related cognitive decline," wrote the authors of newly published study results showing that use of the herbal supplement for several years in patients age 72-96 did not result in a slower rate of cognitive decline than placebo.

Beth E. Snitz, PhD, University of Pittsburgh, and colleagues found these results by analyzing outcomes from the Ginkgo Evaluation of Memory (GEM) study to see if the supplement slowed cognitive decline in those participants who had normal cognition or mild cognitive impairment at the start of the study. GEM—for which earlier results showed ginkgo biloba to not be effective in reducing incidence of Alzheimer’s dementia or overall dementia—was a randomized, double-blind, placebo-controlled trial of 3,069 participants who were given 120mg of the supplement or an identical-appearing placebo twice daily between 2000 and 2008, with a median follow-up of 6.1 years.

The current analysis found “no evidence for an effect of G biloba on global cognitive change and no evidence of effect on specific cognitive domains of memory, language, attention, visuospatial abilities and executive functions.”

The authors concluded that they found “no evidence that G biloba slows the rate of cognitive decline in older adults. These findings are consistent with previous smaller studies examining prevention of decline and facilitation of cognitive performance and with the 2009 Cochrane review of G biloba for dementia and cognitive impairment."

Related Videos
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Depression Screening: Challenges and Solutions at the Primary Care Level
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
© 2024 MJH Life Sciences

All rights reserved.